Endovascular treatment in the multimodality management of brain arteriovenous malformations: report of the Society of NeuroInterventional Surgery Standards and Guidelines Committee.
Angiography
Brain
Embolic
Malformation
Standards
Journal
Journal of neurointerventional surgery
ISSN: 1759-8486
Titre abrégé: J Neurointerv Surg
Pays: England
ID NLM: 101517079
Informations de publication
Date de publication:
Nov 2022
Nov 2022
Historique:
received:
13
01
2022
accepted:
07
03
2022
pubmed:
14
4
2022
medline:
19
10
2022
entrez:
13
4
2022
Statut:
ppublish
Résumé
The purpose of this review is to summarize the data available for the role of angiography and embolization in the comprehensive multidisciplinary management of brain arteriovenous malformations (AVMs METHODS: We performed a structured literature review for studies examining the indications, efficacy, and outcomes for patients undergoing endovascular therapy in the context of brain AVM management. We graded the quality of the evidence. Recommendations were arrived at through a consensus conference of the authors, then with additional input from the full Society of NeuroInterventional Surgery (SNIS) Standards and Guidelines Committee and the SNIS Board of Directors. The multidisciplinary evaluation and treatment of brain AVMs continues to evolve. Recommendations include: (1) Digital subtraction catheter cerebral angiography (DSA)-including 2D, 3D, and reformatted cross-sectional views when appropriate-is recommended in the pre-treatment assessment of cerebral AVMs. Although the quality of evidence is lower than for more common conditions subjected to multiple randomized controlled trials, endovascular therapy has an important role in the management of brain AVMs. Prospective studies are needed to strengthen the data supporting these recommendations.
Sections du résumé
BACKGROUND
BACKGROUND
The purpose of this review is to summarize the data available for the role of angiography and embolization in the comprehensive multidisciplinary management of brain arteriovenous malformations (AVMs METHODS: We performed a structured literature review for studies examining the indications, efficacy, and outcomes for patients undergoing endovascular therapy in the context of brain AVM management. We graded the quality of the evidence. Recommendations were arrived at through a consensus conference of the authors, then with additional input from the full Society of NeuroInterventional Surgery (SNIS) Standards and Guidelines Committee and the SNIS Board of Directors.
RESULTS
RESULTS
The multidisciplinary evaluation and treatment of brain AVMs continues to evolve. Recommendations include: (1) Digital subtraction catheter cerebral angiography (DSA)-including 2D, 3D, and reformatted cross-sectional views when appropriate-is recommended in the pre-treatment assessment of cerebral AVMs.
CONCLUSIONS
CONCLUSIONS
Although the quality of evidence is lower than for more common conditions subjected to multiple randomized controlled trials, endovascular therapy has an important role in the management of brain AVMs. Prospective studies are needed to strengthen the data supporting these recommendations.
Identifiants
pubmed: 35414599
pii: neurintsurg-2021-018632
doi: 10.1136/neurintsurg-2021-018632
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1118-1124Investigateurs
Steven Hetts
(S)
Justin Fraser
(J)
Seon-Kyu Lee
(SK)
Sameer Ansari
(S)
Robert Starke
(R)
Charles Prestigiacomo
(C)
Reade De Leacy
(R)
Clemens Schirmer
(C)
Neil Haranhalli
(N)
Ketan Bulsara
(K)
Stavropoula Tjoumakaris
(S)
Fawaz Al-Mufti
(F)
Michael Chen
(M)
J Mocco
(J)
Mahesh Jayaraman
(M)
Guilherme Dabus
(G)
Michael Froehler
(M)
Peter Kan
(P)
Reade De Leacy
(R)
Stavropoula Tjoumakaris
(S)
Sandra Narayanan
(S)
William Mack
(W)
Richard Klucznik
(R)
Justin Fraser
(J)
Jenny Tsai
(J)
Johanna Fifi
(J)
Felipe Albuquerque
(F)
Blaise Baxter
(B)
Sameer Ansari
(S)
Steven Hetts
(S)
Informations de copyright
© Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: SWH research is supported by NIH (R01CA194533, R42CA265316, R01EB012031). SWH has consulting agreements with Medtronic, Kaneka, Imperative, and Cerenovus. SWH’s institution has contract and grant support from Siemens, Stryker Neurovascular, and Route 92. SAA research is supported by NIH (R01NS114632, R01HL149787, R01HL115267). SAA has consulting agreements with Medtronic, Boston Scientific, Microvention, Rapid Medical, and Imperative Care. RDL has research grant support from Kaneka. RDL has consulting contracts with Cerenovus, Asahi Intec, Imperative Care, Spartan Micro and Stryker. RDL has equity interest in Synchron, Spartan Micro, Endostream, Vastrax and Q’Apel. CMS has research support from Penumbra and ownership interest in NTI.